May 4, 2016

BMC Medicine monthly contents – March 2016

BMC Medicine
Impact Factor: 7.356
Editor: Sabina Alam

Dear Dr Wirawan,

We are pleased to share with you our March content update, featuring journal news, top articles and our most recent table of contents.

From the BMC Medicine blog

The ISRCTN Registry – Leaving No Trial Behind
The ISRCTN Registry – Leaving No Trial Behind

Reported discrepancies between the information provided when the trial is registered and the data reported in publications is becoming a hot topic - especially with regards to outcome switching in randomised controlled trials. Updating the clinical trial record could be that missing link that differentiates between selective reporting and transparency of research.

Tuberculosis – why an ancient disease is a modern day problem
Tuberculosis – why an ancient disease is a modern day problem

Every year on 24th March, World TB Day aims to raise awareness about the disease, and this year focuses on ending TB through collaborative efforts. In recognition of this, we launched a new article collection, guest edited by leading TB researchers from UCL and LSHTM, which highlights some of the latest findings and debates in TB research.

Can we eradicate TB by 2035?
Can we eradicate TB by 2035?

David Moore, author of research published in BMC Medicine's tuberculosis series, talks of how new research tools could help towards eradicating tuberculosis. This blog was originally posted on the London School of Hygiene & Tropical Medicine's website.

Table of Contents


So close: remaining challenges to eradicating polio

Reporting transparency: making the ethical mandate explicit

Zika virus and neurologic autoimmunity: the putative role of gangliosides

Living cumulative network meta-analysis to reduce waste in research: A paradigmatic shift for systematic reviews?


TIME Impact – a new user-friendly tuberculosis (TB) model to inform TB policy decisions


Uniting to end the TB epidemic: advances in disease control from prevention to better diagnosis and treatment


Policy implications of marked reversals of population life expectancy caused by substance use

"Why me, why now?" Using clinical immunology and epidemiology to explain who gets nontuberculous mycobacterial infection

Question and answer

World TB Day 2016: an interview with leading experts in tuberculosis research


Single low dose primaquine to reduce gametocyte carriage and Plasmodium falciparum transmission after artemether-lumefantrine in children with asymptomatic infection: a randomised, double-blind, placebo-controlled trial

The impact of being homeless on the unsuccessful outcome of treatment of pulmonary TB in São Paulo State, Brazil

The timing of tuberculosis after isoniazid preventive therapy among gold miners in South Africa: a prospective cohort study

Tuberculosis incidence is high in HIV-infected African children but is reduced by co-trimoxazole and time on antiretroviral therapy

Interpreting whole genome sequencing for investigating tuberculosis transmission: a systematic review

Detection of lipoarabinomannan (LAM) in urine is an independent predictor of mortality risk in patients receiving treatment for HIV-associated tuberculosis in sub-Saharan Africa: a systematic review and meta-analysis

Towards better guidance on caseload thresholds to promote positive tuberculosis treatment outcomes: a cohort study

A new trial design to accelerate tuberculosis drug development: the Phase IIC Selection Trial with Extended Post-treatment follow-up (STEP)

Mycobacterium tuberculosis whole genome sequencing and protein structure modelling provides insights into anti-tuberculosis drug resistance

Rationing tests for drug-resistant tuberculosis – who are we prepared to miss?

Analysis of vaccination campaign effectiveness and population immunity to support and sustain polio elimination in Nigeria

Is there continued evidence for an association between abacavir usage and myocardial infarction risk in individuals with HIV? A cohort collaboration


Diagnostic 'omics' for active tuberculosis

The impact of migration on tuberculosis epidemiology and control in high-income countries: a review

Clinical use of whole genome sequencing for Mycobacterium tuberculosis

Benefits of Publishing With Us

2015 median turnover times: initial decision three days; first decision after peer review 40 days
Portable peer review
Broad medical readership

Follow @BMCMedicine on Twitter